Related Experiment Video
Updated: Mar 30, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Monocyte to high-density lipoprotein ratio as a new prognostic marker in patients with STEMI undergoing primary
Mehmet Baran Karataş1, Yiğit Çanga1, Kazım Serhan Özcan2
1Department of Cardiology, Siyami Ersek Thoracic and Cardiovascular Surgery Center Training and Research Hospital, Istanbul, Turkey.
Insights
The monocyte to HDL ratio (MHR) can predict heart attack outcomes. Higher MHR levels are linked to increased risk of major adverse cardiac events and mortality in ST-elevation myocardial infarction patients treated with primary PCI.
Area of Science:
- Cardiology
- Biomarkers
- Inflammation Research
Background:
- The monocyte to high-density lipoprotein ratio (MHR) is an emerging indicator of inflammation and oxidative stress.
- Its prognostic value in ST-segment elevation myocardial infarction (STEMI) requires further investigation.
Purpose of the Study:
- To investigate the prognostic significance of MHR in patients with STEMI undergoing primary percutaneous coronary intervention (PCI).
Main Methods:
- Retrospective analysis of 513 STEMI patients treated with primary PCI.
- Collected demographic, clinical, and laboratory data, including admission MHR.
- Assessed in-hospital major adverse cardiac events (MACE) and mortality as outcomes.
Main Results:
- In-hospital mortality occurred in 5% of patients, and MACE in 17%.
- Patients in the highest MHR tertile had significantly higher rates of mortality and MACE compared to the lowest tertile.
- Increased MHR independently predicted in-hospital mortality and MACE in multivariate analysis.
Conclusions:
- Admission MHR is an independent predictor of in-hospital MACE and mortality in STEMI patients treated with primary PCI.
- MHR serves as a valuable prognostic biomarker in this patient population.
Background:
Monocyte count to high-density lipoprotein ratio (MHR) has recently emerged as an indicator of inflammation and oxidative stress in the literature. We aimed to investigate the prognostic value of MHR in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention (PCI).
Methods:
A total of 513 patients who were hospitalized with diagnosis of acute ST-segment elevation myocardial infarction and treated with primary PCI were retrospectively enrolled in the study. Demographic and clinical data, admission laboratory parameters, and MHR values were recorded. Inhospital major adverse cardiac events (MACE) and mortality were reported as the clinical outcomes.
Results:
Twenty-six patients (5%) died, and MACE was observed in 86 patients (17%) during hospital follow-up. Patients were categorized in 3 groups according to tertiles of admission MHR. The rates of inhospital mortality and MACE were significantly higher in tertile 3 group compared to tertile 1 group (10% vs 1%, 27% vs 11%; P < .01 and P < .01). In multivariate regression analysis, age, sex, presence of Killip 3 or 4, left ventricular ejection fraction, troponin I, C-reactive protein, and increased MHR levels (odds ratio, 1.03; 95% confidence interval, 1.01-1.05; P < .01) independently predicted inhospital mortality; age, presence of Killip 3 or 4, troponin I, and increased MHR levels (odds ratio, 1.02; 95% confidence interval, 1.01-1.04; P < .01) independently predicted MACE.
Conclusion:
Admission MHR values were found to be independently correlated with inhospital MACE and mortality after primary PCI.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
04:41Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
